ClinicalTrials.gg
Status unknownNCT06127537Updated Nov 13, 2023

Study on the Efficacy of HE and Therapeutic Group Factors on CR and QoL

An interventional study of Therapeutic Intervention Group in Cardiac Rehabilitation, sponsored by Universidad de Extremadura. Status unknown at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-13.

Sponsored by Universidad de Extremadura · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2023), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Oct 2021, registered Sep 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomised study evaluates the efficacy of health education and therapeutic group factors on cardiac rehabilitation and quality of life in coronary patients attending cardiac rehabilitation programmes in Extremadura.

Read the detailed description

Cardiac rehabilitation has been shown to be effective in improving the quality of life of patients who have suffered a cardiovascular event, as well as in preventing future cardiovascular events, demonstrating an increase in survival of between 20% and 30%, with a Class IA recommendation. Due to the prevalence of cardiovascular disease, both nationally and globally, it is important to study the benefits of these cardiac rehabilitation programmes in order to encourage their use. However, several studies have shown that for the programme to be effective, 5% to 10% weight loss must be achieved in patients, adequate nutritional education must be implemented, and behavioural and psychological intervention programmes must be incorporated in order to have an impact on adherence, psychological well-being, and coping with exercise intolerance. This project aims to study the effectiveness of health education and therapeutic group factors in cardiac rehabilitation and on quality of life in coronary patients in Cardiac Rehabilitation Units in Extremadura, including in the analysis anthropometric and body composition, nutritional, cognitive, emotional and lifestyle factors, which could act as mediators of cardiac function, reactivity to neuro-cardiovascular stress, anxiety, depression, anger-hostility, rehospitalisation, adherence, and adherence to treatment.

02

Conditions studied

  • Cardiac Rehabilitation

Keywords

  • Quality of Life
  • Cardiovascular Disease
  • Health Education
03

In context

Cardiovascular Diseases

5,025 studies on the registry are indexed under Cardiovascular Diseases; 930 are open to participants now.

This study's planned enrollment of 200 is above the median of 100 across 2,801 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Universidad de Extremadura is the lead sponsor of 39 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of coronary heart disease, referred to the "Cardiac Prevention and Rehabilitation Unit".

Exclusion criteria

Exclusion Criteria:

  • Patients with disabling psychiatric disorders.
  • Existence of pacemaker or automatic defibrillator.
  • Presence of pregnancy or breastfeeding.
  • Presence of medical conditions related to oncological conditions requiring chronic treatment with drugs or other substances.
  • Any condition that, in the opinion of the investigators, would disqualify the subject from participation in the study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
200 participants (estimated)

Study arms

  • No intervention
    Control Group

    Health Education Programme in cardiac rehabilitation without a Therapeutic Intervention Group

  • Experimental
    Experimental Group

    Health Education Programme in cardiac rehabilitation with a Therapeutic Intervention Group

    Behavioral: Therapeutic Intervention Group

Interventions

  • BehavioralTherapeutic Intervention Group

    The therapeutic group factors that are worked on in the group session with a psychologist are: * Altruism. * Cohesion: feeling of belonging and acceptance in a group. * Universality: identification with the feelings, ideas or problems of the other group members. * Interpersonal-internalisation learning: the patient understands himself/herself by sharing his/her experience with the group. * Interpersonal-externalisation learning: the group offers the patient the possibility to express his own experience and to change his attitudes towards others. * Counselling. * Identification: assumption of behavioural patterns of other members as one's own. * Reactualisation of the family experience. * Understanding of one's own internal motivations. * Reciprocal stimulation: the improvement of other members encourages them to solve or approach their problems in a more favourable way. * Existential factors: empowerment of the individual.

06

What researchers measure

Primary outcomes

  1. Changes in basal cardiac function and stress reactivity at 8 weeks

    Changes in heart rate (bpm) are monitored at rest, during treadmill or stationary bicycle exercise and in recovery (by ergometry - PEG).

    Time frame: 0 and 8 weeks

  2. Changes in blood pressure over 8 weeks

    Changes in blood pressure (mmHg) are monitored at rest, during exercise on a treadmill or stationary bike and in recovery. (by ergometry - PEG).

    Time frame: 0 and 8 weeks

  3. Change in cardiovascular health indicators over 8 weeks

    Change in the Fuster-BEWAT score (FBS): this index is derived from cardiovascular health indicators blood pressure (mmHg), physical activity (METs), body mass index (kg/m2), fruit and vegetable consumption, and smoking status; 0-1 indicates poor cardiovascular health; 2-3, intermediate; and 4-5, ideal.

    Time frame: 0 and 8 weeks

  4. Changes in physical activity at 8 weeks

    Changes in physical activity using the International Physical Activity Questionnaire (IPAQ): Weekly activity is recorded in Mets (Metabolic Task Equivalent or Metabolic Rate Units) per minute per week (Cat 1 - Low: \<25 Mets / Cat 2 - Moderate: 25-600 Mets / Cat 3 - High: \>1500 Mets).

    Time frame: 0 and 8 weeks

  5. Changes in maximum prehensile strength over 8 weeks

    Changes in maximal upper limb prehensile strength by dynamometry (kg).

    Time frame: 0 and 8 weeks

  6. Changes in quality of life indicators over 8 weeks

    Changes in the Spanish Quality of Life Questionnaire scores in post-infarction patients will be studied. The score per item ranges from 1 (never) to 5 (always). The minimum score is 40 (best health status) and the maximum 200 points (worst health status).

    Time frame: 0 and 8 weeks

  7. Changes in Physical Function quality score over 8 weeks

    Items from the SF36 (Short Form 36) survey. The analysis of the responses is based on the calculation for domain with a scale between 0 (worst health status) and 100 (best health status), after coding, aggregation and transformation of the items that make up each domain.

    Time frame: 0 and 8 weeks

  8. Changes in Physical Role quality score over 8 weeks

    Items from the SF36 (Short Form 36) survey. The analysis of the responses is based on the calculation for domain with a scale between 0 (worst health status) and 100 (best health status), after coding, aggregation and transformation of the items that make up each domain.

    Time frame: 0 and 8 weeks

  9. Changes in Bodily Pain quality score over 8 weeks

    Items from the SF36 (Short Form 36) survey. The analysis of the responses is based on the calculation for domain with a scale between 0 (worst health status) and 100 (best health status), after coding, aggregation and transformation of the items that make up each domain.

    Time frame: 0 and 8 weeks

  10. Changes in General Health quality score over 8 weeks

    Items from the SF36 (Short Form 36) survey. The analysis of the responses is based on the calculation for domain with a scale between 0 (worst health status) and 100 (best health status), after coding, aggregation and transformation of the items that make up each domain.

    Time frame: 0 and 8 weeks

  11. Changes in Vitality quality score over 8 weeks

    Items from the SF36 (Short Form 36) survey. The analysis of the responses is based on the calculation for domain with a scale between 0 (worst health status) and 100 (best health status), after coding, aggregation and transformation of the items that make up each domain.

    Time frame: 0 and 8 weeks

  12. Changes in Social Function quality score over 8 weeks

    Items from the SF36 (Short Form 36) survey. The analysis of the responses is based on the calculation for domain with a scale between 0 (worst health status) and 100 (best health status), after coding, aggregation and transformation of the items that make up each domain.

    Time frame: 0 and 8 weeks

  13. Changes in Emotional Role and Mental Health quality score over 8 weeks

    Items from the SF36 (Short Form 36) survey. The analysis of the responses is based on the calculation for domain with a scale between 0 (worst health status) and 100 (best health status), after coding, aggregation and transformation of the items that make up each domain.

    Time frame: 0 and 8 weeks

  14. Changes in Health perception over 8 weeks

    Changes in health perception will be calculated from the score of the Spanish Quality of Life Questionnaire in post-infarction patients. The score per item ranges from 1 (never) to 5 (always). The minimum score is 40 (best health status) and the maximum 200 points (worst health status).

    Time frame: 0 and 8 weeks

Secondary outcomes

  1. Changes in body weight composition over 8 weeks

    Total patient weight are measured as a kilogram (kg).

    Time frame: 0 and 8 weeks

  2. Changes in body fat mass composition over 8 weeks

    Total patient body fat mass are measured as a kilogram (kg).

    Time frame: 0 and 8 weeks

  3. Changes in body fat-free mass composition over 8 weeks

    Total patient body fat-free mass are measured as a kilogram (kg).

    Time frame: 0 and 8 weeks

  4. Changes in estimated total body water composition over 8 weeks

    Total patient estimated total body water are measured as a kilogram (kg).

    Time frame: 0 and 8 weeks

  5. Changes in protein composition over 8 weeks

    Total patient protein are measured as a kilogram (kg).

    Time frame: 0 and 8 weeks

  6. Changes in bone mineral composition over 8 weeks

    Total patient bone mineral are measured as a kilogram (kg).

    Time frame: 0 and 8 weeks

  7. Changes in Body Mass Index over 8 weeks

    Weight (kg) and Height (m) will be combined to report BMI in kg/m\^2.

    Time frame: 0 and 8 weeks

  8. Changes in CUN-BAE index over 8 weeks

    CUN-BAE are calculated as -44.988+(0.503×age) +(10.689 ×sex) +(3.172×BMI) -(0.026×BMI2) +(0.181×BMI×sex) -(0.02×BMI×age) -(0.005×BMI2 ×sex) +(0.00021×BMI2×age), where male=0 and female=1 for sex, measuring age in years.

    Time frame: 0 and 8 weeks

  9. Changes in phase angle bioimpedance over 8 weeks

    Phase angle is measured in degrees (º).

    Time frame: 0 and 8 weeks

  10. Changes in the percentage of carbohydrates ingested over 8 weeks

    A standardised food consumption questionnaire will be used to assess dietary habits, which collects food intake over 7 days. The weekly nutrient intake will be transformed into "Food Composition Tables". The value obtained will be the percentage of carbohydrates (%).

    Time frame: 0 and 8 weeks

  11. Changes in the percentage of fat ingested over 8 weeks

    A standardised food consumption questionnaire will be used to assess dietary habits, which collects food intake over 7 days. The weekly nutrient intake will be transformed into "Food Composition Tables". The value obtained will be the percentage of fat ingested (%).

    Time frame: 0 and 8 weeks

  12. Changes in the percentage of protein ingested over 8 weeks

    A standardised food consumption questionnaire will be used to assess dietary habits, which collects food intake over 7 days. The weekly nutrient intake will be transformed into "Food Composition Tables". The value obtained will be the percentage of protein ingested (%).

    Time frame: 0 and 8 weeks

  13. Changes in the percentage of vitamins ingested over 8 weeks

    A standardised food consumption questionnaire will be used to assess dietary habits, which collects food intake over 7 days. The weekly nutrient intake will be transformed into "Food Composition Tables". The value obtained will be the percentage of vitamins ingested (%).

    Time frame: 0 and 8 weeks

  14. Changes in kilocalorie intake over 8 weeks

    A standardised food consumption questionnaire will be used to assess dietary habits, which collects food intake over 7 days. The weekly nutrient intake shall be transformed into "Food composition tables". The value obtained will be the number of kilocalories ingested (kcal).

    Time frame: 0 and 8 weeks

  15. Changes in adherence to the Mediterranean diet over 8 weeks

    Changes in adherence to the Mediterranean diet. This will be studied using the Mediterranean Diet Adherence Questionnaire, which consists of 15 items with values ranging from \<9 (low adherence) to \>=9 (good adherence).

    Time frame: 0 and 8 weeks

  16. Changes in erythrocyte parameters over 8 weeks

    Erythrocyte parameters are measured as a percentage \[%\]

    Time frame: 0 and 8 weeks

  17. Changes in glucose level over 8 weeks

    Glucose is measured as a milligrams per decilitre \[mg/dl\]

    Time frame: 0 and 8 weeks

  18. Changes in plasma albumin parameters over 8 weeks

    Plasma albumin are measured as a \[g/dl\]

    Time frame: 0 and 8 weeks

  19. Changes in total lymphocyte over 8 weeks

    Total lymphocyte count are measured as a percentage \[%\]

    Time frame: 0 and 8 weeks

  20. Changes in total triglycerides levels over 8 weeks

    Total lymphocyte count are measured as a milligrams per decilitre \[mg/dl\]

    Time frame: 0 and 8 weeks

  21. Changes in total cholesterol level over 8 weeks

    Total cholesterol are measured as a milligrams per decilitre \[mg/dl\]

    Time frame: 0 and 8 weeks

  22. Changes in high-density lipoproteins levels over 8 weeks

    High-density lipoproteins are measured as a milligrams per decilitre \[mg/dl\]

    Time frame: 0 and 8 weeks

  23. Changes in low-density lipoproteins levels over 8 weeks

    Low-density lipoproteins are measured as a milligrams per decilitre \[mg/dl\]

    Time frame: 0 and 8 weeks

  24. Changes in psychological parameters over 8 weeks

    Changes in STATE-TRAIT ANXIETY scores measured by the State-Trait Anxiety Questionnaire (STAI). It consists of 40 items divided into 2 subscales: trait and state, with Likert-type responses from 0 to 3. The score can range from 0 to 60. There are no cut-off points, but the direct scores are transformed into centiles according to sex and age.

    Time frame: 0 and 8 weeks

  25. Changes in adherence over 8 weeks

    Change in Morisky Green Test scores. It consists of 4 items. The patient is considered to be compliant if he/she answers correctly to all 4 items. Parameter will be measured as compliant / not compliant-

    Time frame: 0 and 8 weeks

07

Study locations

1 of 1 sites recruiting
  • Servicio Extremeño de Salud
    Badajoz, 06006, Spain
    • Francisco J Rodríguez Velasco, PhD · Contact · fcorodriguezv@unex.es · +34 924289839
    • María Yuste Domínguez, MD · Contact · maria.yusted@salud-juntaex.es · +34 924218100
    • Francisco J Rodríguez Velasco, PhD · Principal investigator
    • Guadalupe Gil Fernández, PhD · Sub investigator
    • Celia Redondo Rodríguez, PhD · Sub investigator
    • José A Becerra Mejías, PhDCandidate · Sub investigator
    • Luis M Lara Godoy, RN · Sub investigator
    • María Yuste Domínguez, MD · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06127537
Lead sponsor
Universidad de Extremadura
Collaborators
European Regional Development Fund
Responsible party
Francisco Jose Rodriguez Velasco (Professor PhD, University of Extremadura, Universidad de Extremadura) — Principal investigator
First posted
Nov 13, 2023
Start date
Oct 1, 2021
Primary completion
Jan 31, 2024 (estimated)
Completion
Jun 16, 2024 (estimated)
Last update
Nov 13, 2023

Study contacts

Francisco J Rodríguez Velasco, PhD
Contact
fcorodriguezv@unex.es
+34 924289839 ext. 89839
Guadalupe Gil Fernández, PhD
Contact
ggilfer@unex.es
+34 924489674 ext. 86674
Francisco J Rodríguez Velasco, PhD
principal investigator · University of Extremadura

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion